Currently Viewing:
ISPOR 2019
Panelists Discuss the Potential and Pitfalls of Disruption in Healthcare
May 20, 2019
Trends in Value That Dr Daniel Mullins Expects to See in Coming Years
May 21, 2019
Dr Jon Campbell Discusses the Need for More Creative Methods of Value Assessment
May 21, 2019
The Imperfect QALY: How It's Used Depends on Where You Enter Value Discussions
May 21, 2019
Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease
May 22, 2019
Panelists Debate the Role of ICER: Useful Overseer of Prices, or Oppressor of Choice?
May 22, 2019
Bringing Financial Theory Into the Value Equation of Future Cutting-Edge Therapies
May 22, 2019
Currently Reading
Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment
May 22, 2019
Dr Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points
May 23, 2019
Dr Eleanor Perfetto Outlines Criticisms of the QALY
May 23, 2019
New Therapies Offer Possible Cures but Pose Affordability Challenges
May 23, 2019
Fremanezumab Cost Effective for Both Types of Migraine, Researchers Say
May 27, 2019
Dr Jon Campbell on Benefits of Using MCDA in Value Assessment
June 03, 2019
Dr Nicholas Robert Explains the Need to Standardize Use of RWE for Measuring Clinical End Points
June 23, 2019
Dr Devin Incerti: Use Value Assessments to Maximize the Well-Being of a Population
July 14, 2019
Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data
July 16, 2019
Dr Eleanor Perfetto on Ways to Improve Transparency, Education Around Value Assessment
July 23, 2019
Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs
July 29, 2019
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
August 10, 2019
Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs
August 22, 2019

Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment

Devin Incerti, PhD, lead economist, Innovation and Value Initiative, discusses lessons learned and best practices that have emerged as a result of different approaches to value assessment.


Devin Incerti, PhD, lead economist, Innovation and Value Initiative, discusses lessons learned and best practices that have emerged as a result of different approaches to value assessment.

Transcript

Looking at different approaches to value assessment, what lessons learned and best practices have emerged?

One of the most common ways to do value assessment is what I would call a conventional cost-effectiveness analysis. This is used particularly in Europe, but really around the world, and they’ve been doing it for the last 40 years or so. What that means is that the methods are very well-established, we have good ways to do it, and it lets us help guide decision making. We can use it to set prices, we can use it to make coverage decisions, we can assess uncertainty. If you’re a decision maker, you might not want to just make a decision; you might want to know the uncertainty you have with that decision, and luckily those methods let us do that.

One other thing: the conventional cost-effectiveness lets us think about opportunity costs, which is, in my mind, a very important concept. If you’re introducing a new technology, it’s not free. There’s something else you could have done instead. You might have to displace a particular investment that’s already there. You might have to spend less on healthcare, or more on healthcare and less on other goods and services in the economy. And cost-effectiveness lets us do all of those things.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up